Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Vicadrostat and Empagliflozin
NCT07035457Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicadrostat in chronic kidney disease (CKD) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity and Maximum measured concentration. Started Jul 2025; status: completed.
02
Drugs
vicadrostat
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07035457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07035457.